May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Intravitreal Injection of Bevacizumab for Macular Edema Associated With Central Retinal Vein Occlusion
Author Affiliations & Notes
  • H. Kawamura
    Ophthalmology, Shiga University of Medical Science, Otsu, Japan
  • O. Sawada
    Ophthalmology, Shiga University of Medical Science, Otsu, Japan
  • M. Kakinoki
    Ophthalmology, Shiga University of Medical Science, Otsu, Japan
  • T. Sawada
    Ophthalmology, Shiga University of Medical Science, Otsu, Japan
  • M. Ohji
    Ophthalmology, Shiga University of Medical Science, Otsu, Japan
  • Footnotes
    Commercial Relationships H. Kawamura, None; O. Sawada, None; M. Kakinoki, None; T. Sawada, None; M. Ohji, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 305. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H. Kawamura, O. Sawada, M. Kakinoki, T. Sawada, M. Ohji; Intravitreal Injection of Bevacizumab for Macular Edema Associated With Central Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2007;48(13):305.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: Macular edema is a major cause of visual loss in patients with central retinal vein occlusion (CRVO). Vascular endothelial growth factor (VEGF) plays a role in causing macular edema. Bevacizumab, an antibody to VEGF, is effective for the treatment of macular edema. In this study, we assessed the short-term efficacy of intravitreal bevacizumab for macular edema associated with CRVO.

Methods:: Five consecutive patients (5 eyes) (mean age, 72.0 years; standard deviation, 9.6 years) received an intravitreal injection of bevacizumab (1.25 mg). The patients underwent visual acuity (VA) testing and optical coherence tomography (OCT) imaging at baseline, 1 or 2 weeks, and 1 and 3 months. The retinal thickness was assessed by OCT.

Results:: No adverse effects were observed. At 1 or 2 weeks, the mean retinal thickness decreased in all patients from 670.4 ± 102.4 µm to 341.4 ± 91.2 µm (p<0.01). The VA improved by 0.3 logMAR unit or more in four patients and was stable in the other patient. The mean VA (logMAR) improved from 1.29 to 0.83 (p<0.05). At 1 month, the mean retinal thickness was 235.2 ± 50.1 µm (p<0.01) and the mean VA (logMAR) was 0.77 (p<0.05). The macular edema recurred in three of the five patients who received another injection of bevacizumab (1.25 mg) at 2 months or later. No significant change in retinal thickness or VA was seen in the other patients at 3 months.

Conclusions:: Our data suggest that intravitreal bevacizumab decreases macular edema and improves VA at least in the short term. Long-term observation is required.

Keywords: edema • macula/fovea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×